The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
At the start of 1944, Major General James Doolittle, the new commander of the 8th Air Force, released most fighters from the requirement of flying in close formation with the bombers, allowing them free rein to attack the Luftwaffe wherever it could be found. The aim was to achieve air supremacy. Mustang groups were sent far ahead of the bombers in a "fighter sweep" to intercept German fighters. Bomber crews complained, but by June, supremacy was achieved. The Luftwaffe's twin-engined Messerschmitt Bf 110 Zerstörer heavy fighters brought up to deal with the bombers proved to be easy prey for the Mustangs, and had to be quickly withdrawn from combat. The Focke-Wulf Fw 190A, already suffering from poor high-altitude performance, was outperformed by the Mustang at the B-17's altitude, and when laden with heavy bomber-hunting weapons and extra armor as a replacement for the more vulnerable twin-engined Zerstörer heavy fighters, these variants had poor manuverability and suffered heavy losses. The Messerschmitt Bf 109 had comparable performance to the P-51 at high altitudes, but its lightweight airframe was even more affected by increases in armament. The Luftwaffe answered with the Gefechtsverband ("battle formation"). This consisted of a Sturmgruppe of heavily armed and armored Fw 190As escorted by two Begleitgruppen of Bf 109s, whose task was to keep the Mustangs away from the Fw 190s as they attacked the bombers. This strategy proved to be problematic, as the large German formation took a long time to assemble and was difficult to maneuver.
Properdin promotes phagocytosis of apoptotic T cells in two ways. One way is through binding to apoptotic T cells, which initiates AP-mediated C3b deposition, promoting cell uptake through CR3-bearing phagocytes. Another way is through properdin binding on T cells and directly mediating phagocytes. Properdin contains abilities to eliminate apoptotic cells in order to reduce harmful inflammatory and autoimmune reactions. Additionally, properdin binds malignant T cell lines, therefore, properdin deficiency may be a risk in the development of specific T cell malignancies. The alternative pathway is not dependent on antibodies. This branch of the complement system is activated by IgA immune complexes and bacterial endotoxins, polysaccharides, and cell walls, and results in producing anaphylatoxins, opsonins, chemotactic factors, and the membrane attack complex, all of which help fight pathogens.
== Etymology and history == From the Greek words baeo (little) and kystis (bladder) 1945 P. baeocystis is first collected in Eugene, Oregon. 1958 P. baeocystis is formally described and published by Singer and Smith. 1962 Psilocin is first reported in this species. 1967-68 Baeocystin and norbaeocystin are discovered and named. 1981 Testing again reveals psilocybin, psilocin, baeocystin and norbaeocystin.
Sources: en.wikipedia.org
Each member of the population typically progresses from susceptible to infectious to recovered. This can be shown as a flow diagram in which the boxes represent the different compartments and the arrows the transition between compartments (see diagram).
The last eukaryotic common ancestor (LECA) is the hypothetical most recent common ancestor of all living eukaryotes – organisms whose cells have a nucleus, around 2 billion years ago. The process by which the LECA came into being, eukaryogenesis, is not understood in detail, but is thought to have involved symbiogenesis, the coming together of an archaean and a bacterium which formed the cell's mitochondria. The LECA's structure and function have been reconstructed by comparing the genomes of modern eukaryotes. This has led biologists to propose that the LECA was a complex cell with a nucleus with a nucleolus and eu/heterochromatin, an endoplasmic reticulum, peroxisomes, endo- and lysosomes, the ESCRT system, a Golgi apparatus, actin-based endo- and exocytosis, pseudopodia or filopodia, sterol-based membranes, G3P + ester bond phospholipids, a microtubule-based cytoskeleton with an organising centre, basal bodies, vacuoles, iron-sulphur cluster biosynthesis via the CIA system, mitochondria, and microtubule-based flagella.
==== Microparticle and nanoparticle synthesis ==== Advanced particles and particle-based materials, such as polymer particles, microcapsules, nanocrystals, and photonic crystal clusters or beads can be synthesized with the assistance of droplet-based microfluidics. Nanoparticles, such as colloidal CdS and CdS/CdSe core-shell nanoparticles, can also be synthesized through multiple steps on a millisecond time scale in a microfluidic droplet-based system. Nanoparticles, microparticles and colloidal clusters in microfluidic devices are useful for functions such as drug delivery. The first particles incorporated in droplet-based systems were silica gels in the micrometer size range in order to test their applications in the manufacturing of displays and optical coatings. Mixing solid particles with aqueous microdroplets requires changes to microfluidic channels such as additional reagent mixes and choice of specific materials such as silica or polymers that do not interfere with the channels and any bioactive substances the droplets contain. The synthesis of copolymers requires milling macroscopic molecules to microparticles with porous, irregular surfaces using organic solvents and emulsification techniques. These droplets preloaded with microparticles can also be quickly processed using UV irradiation. Characterization of these microparticles and nanoparticles involves microimaging for analyzing the structure and the identification of the macroscopic material being milled.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.